Clinical trial NCT06225999: Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas
Official title: A Single-arm Multicentre Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Who Have Not Previously Received Therapy for Metastatic Adenocarcinoma of the Pancreas
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Metastatic Adenocarcinoma of the Pancreas
Lead sponsor: Servier
Sponsor class: INDUSTRY
First posted: 2024-01-26
Enrollment: 41
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is to assess the anti-tumour activity, safety and tolerability of irinotecan liposome injection (S095013) in combination with oxaliplatin, 5-Fluorouracil (5-FU) and levoisomer form of leucovorin (LLV). S095013, oxaliplatin, 5-FU and LLV will be administered on days 1 and 15 of each 28-day cycle. Cycles will continue until clinical or radiological progressive disease, unacceptable study medication-related toxicity or withdrawal from study. During the treatment period participants will have study visits on day 1, 3, 15, and 17 of each cycle, some of which may occur as a home visit. At least 30 days after treatment has ended a end of treatment visit will occur and then participants will be followed for survival every month via telephone or email until death or end of the study. Study visits may include questionnaires, blood and urine tests, ECG, vital signs, physical examination, and administration of study treatment.


Eligibility criteria: Inclusion Criteria:

* Male or non-pregnant and non-lactating female ≥ 18 years of age.
* Histologically or cytologically confirmed adenocarcinoma of the pancreas that has not been previously treated in the metastatic setting.
* Initial diagnosis of metastatic disease (as per American Joint Committee on Cancer 8th Edition \[AJCC 2017\]) must have occurred ≤ 6 weeks prior to screening.
* Participant has one or more metastatic lesions measurable by CT-scan (or MRI), if the participant is allergic to CT contrast media, according to RECIST Version 1.1 criteria.
* ECOG PS of 0 or 1 at screening and within 7 days prior to first dosing.
* Participant has adequate hematological, biochemical, hepatic, and renal function parameters.

Exclusion Criteria:

* Prior treatment of pancreatic cancer in the metastatic setting with surgery, radiotherapy, chemotherapy or investigational therapy (palliative surgery, palliative radiotherapy and placement of biliary stent/tube are permitted).
* Prior treatment of pancreatic adenocarcinoma with chemotherapy in the adjuvant setting, except those where at least 12 months have elapsed since completion of the last dose and no persistent treatment-related relevant toxicities are present.
* Participant has only locally advanced disease.
* Known hypersensitivity to any of the components of irinotecan liposome injection, other liposomal products, or any components of 5-FU, LLV or oxaliplatin products.

Primary outcomes:
measure: Overall Response (OR)
timeFrame: Through the end of study treatment (approximately 16 months after study start)
Secondary outcomes:
Other outcomes:
Locations:
city: Kashiwa
country: Japan
facility: National Cancer Center Hospital East (003)
state: Chiba
city: Chiba
country: Japan
facility: Chiba University Hospital (015)
city: Chiba
country: Japan
facility: Chiba Cancer Center (011)
city: Ehime
country: Japan
facility: National Hospital Organization Shikoku Cancer Center (013)
city: Fukuoka
country: Japan
facility: National Hospital Organization Kyushu Cancer Center (005)
city: Ishikawa
country: Japan
facility: Kanazawa University Hospital (008)
city: Kanagawa
country: Japan
facility: Kanagawa Cancer Center (002)
city: Nagoya
country: Japan
facility: Aichi Cancer Center (007)
city: Osaka
country: Japan
facility: Osaka International Cancer Institute (009)
city: Saitama
country: Japan
facility: Saitama Cancer Center (012)
city: Sapporo
country: Japan
facility: Hokkaido University Hospital (004)
city: Tokyo
country: Japan
facility: National Cancer Center Hospital (001)
city: Tokyo
country: Japan
facility: The Cancer Institute Hospital of JFCR (006)
city: Yamaguchi
country: Japan
facility: Yamaguchi University Hospital (010)
Study officials:
References: